About Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Jazz Pharmaceuticals Plc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments primarily in the areas of sleep medicine, neurology, and hematology. The company is dedicated to addressing significant unmet medical needs by creating therapies that improve patient outcomes and quality of life. Jazz Pharma's portfolio includes a range of pharmaceutical products designed to treat various conditions, with a particular emphasis on disorders related to sleep and central nervous system disorders. Through its research and development initiatives, the company aims to advance the scientific understanding of these conditions and contribute to the broader healthcare landscape. Read More
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ)
jumped 18.3% in the morning session after the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its cancer drug, Ziihera.
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones Industrial Average (DJIA) show signs of modest hesitation. Investors are bracing for a high-stakes week,
Jazz Pharmaceuticals delivered a quarter that exceeded Wall Street’s expectations, with management attributing results to robust demand for Xywav and Epidiolex, as well as the swift and successful launch of Modeyso following its FDA approval. CEO Renée Galá highlighted the company’s execution, noting, "We delivered 2 FDA approvals that underscore Jazz's ability to bring highly differentiated therapies to patients with serious unmet needs." The quarter also saw positive developments in Jazz’s sleep and oncology franchises, reinforced by expanded guidelines and new data, which management believes will support continued growth.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 6.7% year on year to $1.13 billion. The company expects the full year’s revenue to be around $4.23 billion, close to analysts’ estimates. Its non-GAAP profit of $8.13 per share was 39% above analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 6.7% year on year to $1.13 billion. The company expects the full year’s revenue to be around $4.23 billion, close to analysts’ estimates. Its non-GAAP profit of $8.13 per share was 39% above analysts’ consensus estimates.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Jazz Pharmaceuticals trades at $138.50 and has moved in lockstep with the market. Its shares have returned 27.1% over the last six months while the S&P 500 has gained 22.9%.
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
